http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2428211-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be0251ad39723c7aaf05444d302c1f29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_081d8bec25acc40593a52eae6d2df9a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efb35af151163072ce7ce97fbddc0f2a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2007-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aab8a32ea14ece4cf02ff244615305f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b5556e0e0c5db14372b9141cae57467 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d1b31ad7e5f4f7456bc37b567c2cce9 |
| publicationDate | 2011-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2428211-C2 |
| titleOfInvention | Method of treating reperfusion renal damages in oncological patients |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in partial or complete urinary tract obstruction associating renal malfunction in the patients suffering malignant growths. That is ensured by a double biological Perftoran test on the first day after prolonged postrenal obstruction released in the patients suffering developed ischemic-reperfusion renal damage and showing a creatinine level 0.4 mmol/l and more. If observing no anaphylactoid reactions, Perftoran is introduced in dose 2-4 mg/kg of body weight at average speed 40-60 drops a minute. On the third day, the preparation is introduced again in the same dosage if having preserved the creatinine value 0.4 mmol/l and more. n EFFECT: method allows higher clinical effectiveness in renal insufficiency in urinary tract drainage in the oncological patients due to the introduction of the gas-transport preparation in a certain regimen. n 1 ex |
| priorityDate | 2007-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 261.